Sandoz (SDZNY) announced the launch of Pyzchiva in the U.S. The medicine is now commercially available to patients across the U.S.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDZNY:
- Sandoz price target raised to CHF 41 from CHF 35 at Morgan Stanley
- Sandoz downgraded to Neutral from Buy at UBS
- Sandoz price target raised to CHF 41 from CHF 39 at Berenberg
- FDA adds boxed warning to Teva’s Copaxone for allergic reaction
- M&A News: Intra-Cellular Stock Rallies 36% on News of $14.6B Acquisition by Johnson & Johnson
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue